Related Experiment Video
Updated: May 12, 2026
08:13
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
Published on: March 22, 2016
Clinical development of neridronate: potential for new applications
Davide Gatti1, Maurizio Rossini, Ombretta Viapiana
1Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.
Therapeutics and Clinical Risk Management
|April 17, 2013
Summary
Neridronate, an aminobisphosphonate, offers effective treatment for osteogenesis imperfecta (OI) and Paget
Area of Science:
- Pharmacology and Bone Metabolism
- Clinical Therapeutics
Background:
- Neridronate is an aminobisphosphonate approved in Italy for osteogenesis imperfecta (OI) and Paget's disease of bone (PDB).
- Its unique administration flexibility (intravenous and intramuscular) supports homecare settings.
Purpose of the Study:
- To review the most recent clinical findings on neridronate for OI and PDB.
- To evaluate neridronate's efficacy in osteoporosis and other bone conditions.
- To specifically analyze emerging evidence regarding neridronate in complex regional pain syndrome type I (CRPS I).
Main Methods:
- Systematic review of recent clinical studies and evidence.
- Analysis of therapeutic outcomes across various bone-related disorders.
- Focus on data pertaining to complex regional pain syndrome type I.
Main Results:
- Summarizes current clinical data for neridronate in OI and PDB.
- Presents findings on neridronate's application in osteoporosis.
- Highlights new evidence for neridronate's role in CRPS I treatment.
Conclusions:
- Neridronate demonstrates clinical utility in treating OI and PDB.
- Its administration versatility is a significant advantage.
- Further research supports its potential in managing CRPS I and other conditions.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).